Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011008 | 0.75 | EGFR (0.55) | EGFRALDH1A1CYP2A6 | |
| SCHEMBL2010333 | 0.75 | EGFR (0.55) | EGFRKDM4ECYP2A6 | |
| SCHEMBL35632 | 0.74 | EGFR (0.54) | PIK3CGEGFRKDM4EALDH1A1MAPT | |
| SCHEMBL30124132 | 0.74 | EGFR (0.54) | PIK3CGEGFRKDM4EALDH1A1MAPT | |
| SCHEMBL3292267 | 0.73 | PIK3CG (0.47) | PIK3CGEGFRALDH1A1 | |
| SCHEMBL31214569 | 0.73 | NQO2 (0.50) | PIK3CGEGFRKDM4EALDH1A1MAPT | |
| SCHEMBL1378685 | 0.71 | PIK3CG (0.46) | PIK3CGEGFRALDH1A1 | |
| SCHEMBL11479229 | 0.69 | KDM4E (0.48) | EGFRKDM4EALDH1A1PTGS2RAB9A | |
| SCHEMBL9829442 | 0.69 | TDP1 (0.48) | KDM4EALDH1A1MAPTPTGS2RAB9A | |
| SCHEMBL11696316 | 0.69 | ALDH1A1 (0.42) | KDM4EALDH1A1MAPTPTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | PLK1, PLK2, PLK4 | PIK3CG 69/4885EGFR 1397/4885KDM4E 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.